InspireMD FDA Approves CGuard Prime, Restoring U.S. Market Access
InspireMD (NSPR) announced FDA approval of CGuard Prime for TCAR, re-entering the U.S. market. Q3 revenue was $2.242M, down 11.1% YoY, with a net loss of $9.762M. The company has $19.246M in cash. Analysts rate NSPR as Buy with a $4.00 target, but Spark's AI rates it Neutral due to weak profitability and cash burn.
How this was made
The 30-second read
Why it matters
The approval could reverse the recent revenue decline and improve cash flow, but execution risk remains.
Market read
Primary regulatory news for a listed micro‑cap; likely short‑term price move.
What to watch
Potential reimbursement challenges and competition from established stent manufacturers.
Background
InspireMD (NSPR) reported third‑quarter results showing a net loss and minimal U.S. revenue after a recall, but highlighted the FDA approval as a catalyst.
Ticker impact
FDA approval of CGuard Prime restores U.S. market access and adds >35,000 procedures annually.
upward pressure as investors price in new product launch and expanded market opportunity
The approval is a primary regulatory event for a micro‑cap medical device maker; such news historically drives short‑term buying.
Market effects
May boost sentiment for the broader carotid stent and vascular device sector.
Positive for U.S. med‑tech stocks, limited global effect.
Low; impact confined to niche medical device market.
Counterpoint
The company’s cash burn and limited U.S. revenue could limit upside despite approval.
Key entities
- companyInspireMD
Medical device maker focused on carotid stent systems.
- regulatorFDA
U.S. Food and Drug Administration that granted approval.


